SCHEMBL6038804

SCHEMBL6038804

O=S(=O)(Nc1nc2ccccc2nc1OCc1cccnc1)c1ccc(Cl)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.66
KMT2A Q03164 7/20 0.66
ALDH1A1 P00352 4/20 0.54
POLB P06746 3/20 0.54
CCR4 P51679 1/20 0.53
KDM4E B2RXH2 4/20 0.53
HSD17B10 Q99714 3/20 0.53
LMNA P02545 2/20 0.53
NAMPT P43490 1/20 0.48
SCN9A Q15858 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
AR P10275 1/20 0.47
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TP53 P04637 2/20 0.46
TSHR P16473 2/20 0.46
BACE1 P56817 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MAPK1 P28482 1/20 0.46
CASP1 P29466 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6039136 0.91 KDM4E (0.63) MEN1KMT2AALDH1A1CCR4KDM4E
SCHEMBL6039075 0.90 KDM4E (0.53) MEN1KMT2AALDH1A1CCR4KDM4E
SCHEMBL6038408 0.90 MEN1 (0.62) MEN1KMT2APOLBCCR4KDM4E
SCHEMBL6038910 0.90 KDM4E (0.56) MEN1KMT2AALDH1A1POLBCCR4
SCHEMBL6038667 0.89 MEN1 (0.54) MEN1KMT2AALDH1A1CCR4KDM4E
SCHEMBL6038395 0.89 KDM4E (0.57) MEN1KMT2ACCR4KDM4EHSD17B10
SCHEMBL6038776 0.88 MEN1 (0.70) MEN1KMT2AALDH1A1POLBKDM4E
SCHEMBL6038465 0.88 KDM4E (0.54) MEN1KMT2AALDH1A1POLBCCR4
SCHEMBL6038945 0.87 KDM4E (0.50) MEN1KMT2ACCR4KDM4EHSD17B10
SCHEMBL6038697 0.87 LMNA (0.55) MEN1KMT2AALDH1A1POLBCCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 MEN1 2431/4885KMT2A 4190/4885ALDH1A1 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.